Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dutasteride-loaded transfersomes, compared to traditional liposomes, better target hair follicles by releasing the drug in a more controlled manner, as shown in vitro with enhanced follicular targeting (Tf = 0.32 versus 0.15, p < 0.005) using porcine ear skin.

This study observed that mice with a whole-body deficiency of Cystathionine-β-synthase developed severe hyperhomocysteinemia and related mild symptoms without increased mortality, indicating HHCy may not directly cause end organ damage.

Liposomes improve minoxidil delivery to hair follicles, enhancing treatment for hair loss.

This study found that laser Doppler velocimetry can non-invasively predict topical minoxidil response by correlating scalp blood flow changes with sulfotransferase enzyme activity in women with pattern hair loss.

This study discusses the potential of topical retinoids, vitamin A derivatives, to improve treatment outcomes for androgenetic alopecia by promoting hair growth through extending the anagen phase and stimulating follicular activity, offering a promising approach when combined with existing therapies.

This source discusses androgenetic alopecia, noting that male patients may transition from topical minoxidil to its systemic form or from finasteride to dutasteride for potentially better results, while female patients might require extensive lab testing to identify hyperandrogenism due to environmental triggers.

This review discusses current treatment methods for managing androgenetic alopecia in men and women, but reports no new clinical results, highlighting the lack of a standard treatment guide.

In this study, minoxidil significantly downregulated interleukin-1 alpha expression in human keratinocyte cells, suggesting an anti-inflammatory effect that may be a mechanism of action in treating alopecia.

In this study, the researchers reported that a novel exosome-based treatment, EX104, effectively reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, showing results comparable to minoxidil and surpassing it in stimulating capillary growth and follicular proliferation.

This study found that ethosome-loaded minoxidil and tocopherol acetate improved hair regeneration and regulated the microenvironment around hair follicles better than commercial minoxidil in androgenic alopecia model mice, showing promise as a treatment strategy.

This study confirmed that a sulfotransferase enzyme test can effectively rule out 95.9% of nonresponders to 5% topical minoxidil for treating androgenetic alopecia.

This study found topical finasteride and minoxidil both improved hair loss clinically and trichoscopically more effectively than spironolactone in women with female pattern hair loss.

This report discusses the Ninth World Congress for Hair Research and highlights the potential of hair follicle studies to advance understanding of various diseases, with no new clinical results presented.

This study found a perfect correlation between laser Doppler velocimetry measurements of scalp blood perfusion after minoxidil application and sulfotransferase enzyme activity in hair follicles, indicating a potential non-invasive test to predict minoxidil response in female pattern hair loss.

This study found that Minoxidil had biphasic effects on normal human keratinocytes, stimulating proliferation at micromolar doses, but showing antiproliferative, pro-differentiative, and cytotoxic effects at millimolar concentrations.

This review suggests a shift toward genetically informed treatments for male pattern hair loss by integrating genetic insights and pharmacogenetic markers into therapeutic decision-making.

This study concluded that noninvasive imaging techniques offer potential benefits in managing scalp conditions by potentially reducing the need for biopsies and minimizing patient morbidity, each technique having unique advantages and limitations for specific conditions.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

Hormonal therapy is effective for treating acne in adult women, especially with signs of high androgen levels.

This article discusses the ongoing care needs for individuals with 21-hydroxylase deficiency due to mutations in the CYP21A2 gene but does not present new clinical findings.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.

Minoxidil effectively treats hair loss, with better results in women.

In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.

This article reports two cases where 2% topical minoxidil showed promise in treating traction alopecia, but it does not offer broader clinical conclusions.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

This article reviews the role of epithelial-mesenchymal interactions in hair follicle morphogenesis and the hair cycle, suggesting potential paths for developing treatments for hair growth disorders but providing no new clinical findings.

This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This review discusses the steroidogenic properties of human skin and suggests that impaired steroidogenesis may be linked to conditions like acne, rosacea, atopic dermatitis, and androgenic alopecia, but reports no new clinical results.